Urgent

Drug-induced interstitial lung disease

iatrogenic ILD · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Many drugs cause lung injury ranging from pneumonitis and organising pneumonia to fibrosis, including amiodarone, methotrexate, nitrofurantoin, bleomycin and immune-checkpoint inhibitors. Diagnosis is one of exclusion; prompt drug cessation is the cornerstone of treatment.

Red flags

  • Rapidly worsening hypoxaemia / respiratory failure
  • Grade 3-4 checkpoint-inhibitor pneumonitis
  • Failure to improve after 48-72 h of steroids (reconsider infection)
  • Diffuse alveolar haemorrhage features

Assessment

Differential diagnosis

  • Infection (including opportunistic / PJP)
  • Underlying disease progression (e.g. malignancy, connective tissue disease)
  • Cardiogenic pulmonary oedema
  • Radiation pneumonitis
  • Diffuse alveolar haemorrhage
  • Aspiration

Investigations

  • Full drug and timeline history including over-the-counter and recent chemo/immunotherapy
  • HRCT chest to define pattern (ground glass, organising pneumonia, NSIP, fibrosis)
  • Spirometry and DLCO
  • Bronchoscopy with BAL to exclude infection and characterise inflammation
  • Infection screen (cultures, PJP, viral, galactomannan)
  • Autoimmune serology to exclude CTD-ILD

Management

  • Compile a complete medication history and correlate onset with each agent
  • Exclude infection, cardiac failure and disease progression as mimics
  • Obtain HRCT to characterise the injury pattern
  • Perform BAL to exclude infection where safe
  • Stop the suspected culprit drug immediately
  • Assess severity (oxygenation, extent, trajectory) and grade checkpoint-inhibitor pneumonitis
  • Start corticosteroids for symptomatic or moderate-severe pneumonitis
  • For checkpoint-inhibitor pneumonitis, follow immune-toxicity grading and add additional immunosuppression if steroid-refractory
  • Avoid 100% oxygen in bleomycin-exposed patients
  • Document the reaction, avoid rechallenge and monitor recovery with serial imaging/physiology

Drugs & doses

Prednisolone 0.5-1 mg/kg/day PO (up to 1-2 mg/kg for severe/checkpoint pneumonitis) with slow taper
Methylprednisolone 1-2 mg/kg/day IV for severe grade 3-4 checkpoint pneumonitis
Infliximab 5 mg/kg IV or mycophenolate for steroid-refractory immune pneumonitis
Discontinue culprit (amiodarone, methotrexate, nitrofurantoin, bleomycin, checkpoint inhibitor)

Disposition

Admit moderate-severe cases; respiratory +/- oncology (immunotoxicity) MDT; discontinue drug and document reaction.

Complications & pitfalls

  • Respiratory failure requiring ventilation
  • Irreversible pulmonary fibrosis
  • Opportunistic infection on immunosuppression
  • Recurrence on inadvertent rechallenge

Exam pearls

  • Amiodarone lung toxicity can appear months-years after starting and shows high-density pulmonary infiltrates
  • Avoid high FiO2 in bleomycin-exposed patients peri-operatively
  • Checkpoint-inhibitor pneumonitis can occur after therapy has stopped and needs grading-based management
  • Always exclude infection by BAL before attributing to drug and starting steroids

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.